Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)

NCT05400824 | Unknown

• 2 other identifiers: C19-682020A0209435
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France). Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics.

Conditions

Infectious Disease; Cardiovascular Diseases; General Population; Metabolic Disease

Keywords

epidemiology; risk factors; prevalence; cognitive impairment; dengue; hypertension; dyslipidemia; social inequalities; autonomous nervous system

Outcome Measures

Primary Outcomes (2)

• Prevalence of cardiometabolic diseases

  Prevalence rates for diabetes, hypertension, obesity, dyslipidemia, smoking and subclinical atherosclerosis markers

  cross sectional (at inclusion)

• Prevalence of infectious diseases

  Seroprevalence rates for chikungunya, dengue, zika, covid19

  cross sectional (at inclusion)

Study Arms (1)

general population

Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion

Diagnostic Test: Blood, DNA, feces, urine, hair and skin microbiota collection

Interventions

Blood, DNA, feces, urine, hair and skin microbiota collection DIAGNOSTIC_TEST

See above

Also known as: Ewing test, Spirometry, EKG, cognitive, anxiety and depression tests, carotid ultrasound, pulse wave velocity measurement, ankle brachial index measurement

general population

Eligibility Criteria

• Age: 18 Years - 67 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adult men and women ramdomly selected from the voter registration lists in La Réunion island

You may qualify if:

• years
• given consent for genetic analysis,
• written consent for participating in the study

You may not qualify if:

• judicial protection or guardianship

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France: lead

Study Sites (1)

Centre Hospitalier Universitaire de La Réunion

La Réunion, Saint-Pierre, 97448, France

RECRUITING

Related Links

• official website of the French National Institute for Health and Medical Research

MeSH Terms

Conditions

Communicable Diseases; Cardiovascular Diseases; Metabolic Diseases; Cognitive Dysfunction; Dengue; Hypertension; Dyslipidemias

Interventions

Blood Specimen Collection; DNA, B-Form; Defecation; Urination; Spirometry; Electrocardiography; Ultrasonography, Carotid Arteries

Condition Hierarchy (Ancestors)

Infections; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Mosquito-Borne Diseases; Vector Borne Diseases; Arbovirus Infections; Virus Diseases; Flavivirus Infections; Flaviviridae Infections; RNA Virus Infections; Hemorrhagic Fevers, Viral; Vascular Diseases; Lipid Metabolism Disorders

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques; DNA; Nucleic Acids; Nucleic Acids, Nucleotides, and Nucleosides; Nucleic Acid Conformation; Molecular Conformation; Molecular Structure; Biochemical Phenomena; Chemical Phenomena; Genetic Structures; Genetic Phenomena; Digestive System Physiological Phenomena; Digestive System and Oral Physiological Phenomena; Urinary Tract Physiological Phenomena; Reproductive and Urinary Physiological Phenomena; Respiratory Function Tests; Diagnostic Techniques, Respiratory System; Heart Function Tests; Diagnostic Techniques, Cardiovascular; Electrodiagnosis; Ultrasonography; Diagnostic Imaging

Study Officials

• Maxime COURNOT, MD, PhD

  Institut National de la Santé Et de la Recherche Médicale, France

  PRINCIPAL INVESTIGATOR

• Olivier MEILHAC, PhD

  Institut National de la Santé Et de la Recherche Médicale, France

  STUDY DIRECTOR

• Patrick MAVINGUI, PhD

  Institut National de la Santé Et de la Recherche Médicale, France

  STUDY DIRECTOR

Central Study Contacts

Maxime COURNOT

CONTACT

+262262938811; maxime.cournot@inserm.fr

Olivier MEILHAC

CONTACT

+262693406545; olivier.meilhac@inserm.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2022
• First Posted: June 2, 2022
• Study Start: May 1, 2022
• Primary Completion: May 1, 2024
• Study Completion: May 1, 2024
• Last Updated: July 5, 2022

Record last verified: 2022-05

Locations

FR (1)